Alliancebernstein L.P. Trevi Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 4,281,355 shares of TRVI stock, worth $31.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,281,355
Previous 22,340
19064.53%
Holding current value
$31.4 Million
Previous $140,000
16627.86%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
163Shares Held
109MCall Options Held
1.08MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$96.9 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$75.2 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$62.5 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$39 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$32.9 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $428M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...